Shanghai MicroPort Endovascular MedTech Co., Ltd. (SHA:688016)

China · Delayed Price · Currency is CNY

90.38

-2.08 (-2.25%)

Aug 24, 2026, 3:00 PM CST

-25.37% (1Y)

Market Cap	10.92B -25.1%
Revenue (ttm)	1.39B +17.6%
Net Income	588.53M +31.5%
EPS	4.88 +34.8%
Shares Out	120.84M
PE Ratio	18.51
Forward PE	17.37
Dividend	2.30 (2.50%)
Ex-Dividend Date	Jun 5, 2026

Volume	1,543,101
Open	92.40
Previous Close	92.46
Day's Range	90.00 - 92.80
52-Week Range	83.33 - 124.30
Beta	0.05
Analysts	Buy
Price Target	127.25 (+40.79%)
Earnings Date	Aug 27, 2026

About SHA:688016

Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low ... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2012

Employees 822

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688016

Full Company Profile

Financial Performance

In 2025, SHA:688016's revenue was 1.35 billion, an increase of 11.96% compared to the previous year's 1.21 billion. Earnings were 563.33 million, an increase of 12.19%.

Financial Statements

Analyst Summary

According to 6 analysts, the average rating for 688016 stock is "Buy." The 12-month stock price target is ¥127.25, which is an increase of 40.79% from the latest price.

Price Target

¥127.25

(40.79% upside)

Analyst Consensus: Buy

Stock Forecasts